French companion app company Voluntis has partnered with AstraZeneca to develop an app for women undergoing treatment for ovarian cancer. Specifically, the app will help patients and clinicians manage the side effects of a combination therapy of the drugs cediranib and olaparib, which can cause hypertension and diarrhea.
"AstraZeneca has a strong focus on the use of companion devices in drug...
Voluntis's app (not shown here) was one of the first to work with Sanofi's IBGStar connected glucometer.
Paris, France-based Voluntis, a developer of companion apps for medical devices, has raised $29 million in its fourth round of funding. The round was led by Bpifrance Large Venture and international venture capital firm Innovation Capital. Other contributors included Luxemburg-based...
